Document is current
Any future updates will be listed below
-
Authors
Wright, Samuel J.
Zamora, Izabella
Parikh, Milan https://orcid.org/0000-0003-1336-7883
Yeramosu, Deepika
Rucevic, Marijana
Sade-Feldman, Moshe https://orcid.org/0000-0002-0022-0287
LaSalle, Thomas J. https://orcid.org/0000-0002-8390-6072
Blaum, Emily M. https://orcid.org/0000-0002-8656-8216
Liu, Baolin
Bi, Lynn
Kang, Sarah
Blum, Steven M.
Nguyen, Ngan
Guess, Jamey
Kar, Amrita
Schneider, Alexis M. https://orcid.org/0000-0002-2158-6915
Lieb, David
Woods, Elliot
Michaud, William https://orcid.org/0000-0002-3664-2094
Lawless, Aleigha R. https://orcid.org/0009-0009-3861-3164
Sharova, Tatyana
Cohen, Sonia
Kasumova, Gyulnara
Kim, Michelle S.
Cheng, Li-Chun
Villani, Alexandra-Chloé https://orcid.org/0000-0001-7461-0408
Park, Ryan J. https://orcid.org/0000-0003-4725-2937
Jenkins, Russell W. https://orcid.org/0000-0001-6110-2148
Klempner, Samuel J.
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
Flaherty, Keith T. https://orcid.org/0000-0002-3402-0478
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Mehta, Arnav https://orcid.org/0000-0002-0313-2848
Boland, Genevieve M. https://orcid.org/0000-0002-7522-6173
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 15 June 2026
First Online: 24 June 2026
Ethics
Competing interests: A.C.V. has a financial interest in 10× Genomics. 10× Genomics designs and manufactures gene sequencing technology for use in research, and such technology is being used in this research; these interests were reviewed by the Massachusetts General Hospital and Mass General Brigham in accordance with their institutional policies. R.W.J. is a member of the advisory board for and has a financial interest in Xsphera Biosciences Inc., a company focused on using ex vivo profiling technology to deliver functional, precision immune-oncology solutions for patients, providers, and drug development companies. R.W.J. has received honoraria from Incyte (invited speaker), G1 Therapeutics (advisory board), and Bioxcel Therapeutics (invited speaker). R.W.J. has an ownership interest in U.S. patents US20200399573A9 and US20210363595A1. R.W.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. R.J.S. serves as a consultant/advisory board member for Marengo Therapeutics, Merck, Novartis, Pfizer, and Replimune, and has received research funding from Merck. N.H. holds equity in and advises Danger Bio/Related Sciences, is on the scientific advisory board of Repertoire Immune Medicines and CytoReason, owns equity and has licensed patents to BioNtech, and receives research funding from Bristol Myers Squibb, Moderna, JJDC, Takeda, and Calico Life Sciences. A.M. has served a consultant, advisory or board director role for Plexium, SyntheX, Monimoi, Juri Biosciences, CxT Discovery, Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Clasp Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines, and Checkmate Pharmaceuticals, was formerly an Entrepreneur-in-Residence at Third Rock Ventures, is currently a Venture Partner for the Column Group, is a co-founder of Monimoi and Monet Lab, an equity holder in Monimoi, Juri Biosciences, Monet Lab, Clasp Therapeutics, Asher Biotherapeutics and Abata Therapeutics, and has received research funding support from Bristol-Myers Squibb. G.M.B. has sponsored research agreements through her institution with Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals, Astellas, and AstraZeneca. She served on advisory boards for: Iovance, Merck, Moderna, Nektar Therapeutics, Novartis, Replimune, and Ankyra Therapeutics. She consults for: Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics. She holds stock options in Ankyra Therapeutics. The remaining authors declare no competing interests.
